South Korean Biotechs Race to Conquer the Untapped Global MASH Market
Fat accumulation in the liver can trigger severe inflammation even in individuals who completely abstain from alcohol.
Search results for "GLP-1 obesity treatment"
Hanmi Pharm Revives 'LAPSCOVERY' Momentum with $1.26B Eli Lilly Licensing Deal
Hanmi Pharmaceutical has licensed its novel drug candidate sonefpeglutide to global pharmaceutical giant Eli Lilly and Company in a deal valued at up...
Daewoong Pharmaceutical Moves to Develop Once-Monthly GLP-1 Obesity Injection
Daewoong Pharmaceutical is teaming up with a biotech startup to develop an obesity treatment administered by injection...
GLP-1 Weight-Loss Drugs: Potential Metabolic Instability Linked to Long-Term Use
A new study suggests that the long-term administration of GLP-1 receptor agonists—the class of anti-obesity medications...
Taking Wegovy or Mounjaro? Seek Immediate Medical Attention if ‘These Symptoms’ Appear
As anti-obesity medications for weight loss and blood sugar control gain popularity, monitoring and managing potential...
Resistance in the Genes: Why Popular Obesity Drugs Don’t Work for Everyone
GLP-1 receptor agonists like Wegovy and Mounjaro have fundamentally reshaped the treatment of diabetes and obesity.
Can Wegovy and Mounjaro Reduce Cancer Risk?
Global obesity experts have proposed a large-scale, long-term follow-up study to verify whether the use of modern...
HK inno.N’s ‘Ecnoglutide’: Can a Late Entrant’s “Hidden Card” Reshape the Obesity Market?
HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s...
"It Wasn't Just Weight Loss That Improved My Knees"...Ozempic Study Confirms Cartilage 'Metabolic Changes'
"Please lose some weight. " This is a common phrase heard when visiting a hospital for knee pain.
GLP-1 Drugs and Bone Health: Studies Highlight Fracture Risks in Elderly Patients
The GLP-1 receptor agonist class of drugs, widely used for the treatment of obesity and type 2 diabetes, has...